“InThera will provide the next-generation VLP-based vaccines and wish to resolve the unmet medical needs against emerging viral infections”

01Received Grants of High Value-added future Growth Vaccine Development from KHIDI(Vaccine Leading Technology Center)

02Strategic Investment - AMICOGEN Inc.

04Received Grants of Rapid and Universal Vaccine Development Program from KHIDI(Global Vaccine Leading Technology Center)

08Completion of Preclinical Study of Rota-virus Vaccine

10Completion of Preclinical Study of Noro-virus VLP Vaccine

12Received Bridge Investment

02Relocation of R&D Center
(302, Galmachi-ro, Jungwon-gu, Seongnam-si)

05Received Right Fund TAA(Technical Accelerator Award)

10Received Grants of Development of Multivalent Norovirus VLP Vaccine Program from KHIDI(Vaccine Innovative Technology Alliance Korea)

11Received Investment(Series A) from Venture Capital(InterVest.Co.Ltd / Smilegate Investment, Inc.)

01Certification of R&D Center

02Received Investment from Venture Capital

03Certification of Venture Business Entity

05Received Follow-up Investment from Accelerator

08Received Grants of IP-Nare Program

01Received Grants of Start-up Growth Technology Development Program

06Received Grants of TIPS Program(Accelerator : Bluepoint Partners)

09Received Grants from Korea Institute of Start-up and Entrepreneurship Development(KISED)

10Received Grants from MSS for R&D Center Establishment

인테라